CLVSQ
Clovis Oncology Inc

27,011
Loading...
Loading...
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Clovis Oncology Inc?
What is the 52-week high for Clovis Oncology Inc?
What is the 52-week low for Clovis Oncology Inc?
What is Clovis Oncology Inc stock price today?
What was Clovis Oncology Inc stock price yesterday?
What is the PE ratio of Clovis Oncology Inc?
What is the Price-to-Book ratio of Clovis Oncology Inc?
What is the 50-day moving average of Clovis Oncology Inc?

Latest CLVSQ News

View
No CLVSQ news at the moment.

Advertisement|Remove ads.

Advertisement|Remove ads.